Series interpretation to Chinese Expert Consensus on the Diagnosis and Treatment of Acromegaly(2020)(Part 3): Pharmaceutical treatments

VernacularTitle:《肢端肥大症诊治中国专家共识(2020版)》系列解读之三：肢端肥大症的药物治疗
Author: Hai LI ; Yanbing LI
From: Chinese Journal of Endocrinology and Metabolism 2021;37(5):425-428
CountryChina
Language:Chinese
Abstract: Acromegaly is an endocrine and metabolic disease with insidious onset. Delays in its diagnosis and treatment significantly increase the incidence of complications. Early detection, diagnosis, and treatment are extremely important for the prognosis of patients with acromegaly. Based on a large quantity of evidence in recent years, Chinese Expert Consensus on the Diagnosis and Treatment of Acromegaly(2020) has standardized the diagnosis and the treatment strategies of acromegaly. In the non-surgical treatment section, according to the categories of drugs used to treat acromegaly, the indications, selection, administration, dosage and precautions of pharmaceutical treatment have been clarified with specific recommendations. It is hoped that the new consensus can further guide and standardize the clinical management of acromegaly.